- Home
- ACOG vs APLT Comparison
ACOG vs APLT Comparison
Compare ACOG & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACOG
- APLT
- Stock Information
- Founded
- ACOG 2000
- APLT 2016
- Country
- ACOG Canada
- APLT United States
- Employees
- ACOG N/A
- APLT N/A
- Industry
- ACOG
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ACOG
- APLT Health Care
- Exchange
- ACOG Nasdaq
- APLT Nasdaq
- Market Cap
- ACOG 80.3M
- APLT 63.6M
- IPO Year
- ACOG N/A
- APLT 2019
- Fundamental
- Price
- ACOG $8.47
- APLT $0.41
- Analyst Decision
- ACOG Strong Buy
- APLT Buy
- Analyst Count
- ACOG 1
- APLT 6
- Target Price
- ACOG $20.00
- APLT $6.10
- AVG Volume (30 Days)
- ACOG 64.1K
- APLT 771.9K
- Earning Date
- ACOG 11-14-2025
- APLT 11-06-2025
- Dividend Yield
- ACOG N/A
- APLT N/A
- EPS Growth
- ACOG N/A
- APLT N/A
- EPS
- ACOG N/A
- APLT N/A
- Revenue
- ACOG $4,586,341.00
- APLT $121,000.00
- Revenue This Year
- ACOG N/A
- APLT N/A
- Revenue Next Year
- ACOG $149.89
- APLT $5,931.24
- P/E Ratio
- ACOG N/A
- APLT N/A
- Revenue Growth
- ACOG N/A
- APLT N/A
- 52 Week Low
- ACOG $3.75
- APLT $0.30
- 52 Week High
- ACOG $11.54
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ACOG 43.77
- APLT 38.50
- Support Level
- ACOG $8.01
- APLT $0.40
- Resistance Level
- ACOG $10.00
- APLT $0.46
- Average True Range (ATR)
- ACOG 0.56
- APLT 0.03
- MACD
- ACOG 0.05
- APLT -0.01
- Stochastic Oscillator
- ACOG 25.26
- APLT 7.74
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.